Regenxbio Inc
RGNXHealthcare|Biotechnology|USA
$13.95
-1.71 (-10.92%)
Tangible Book
$0.41
Upcoming Data Readouts (6)
Aug 2026
Est. completion
P2P3Duchenne Muscular Dystrophy
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
NCT05693142n=65
Aug 2026
Est. completion
P2Neovascular Age-Related Macular Degeneration (nAMD)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT04514653n=146
Oct 2026
Est. completion
Dec 2026
Est. completion
P2P3AMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
NCT04704921n=671
Dec 2027
Est. completion
P2Diabetic Macular Edema
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
NCT06942520n=18
Apr 2028
Est. completion
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Jun 2026
P2
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550